Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PFE
stocks logo

PFE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.44B
-1.84%
0.603
-4.25%
14.21B
+3.6%
0.774
-15.84%
14.48B
-1.19%
0.729
-6.59%
Estimates Revision
The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.93% over the past three months. During the same period, the stock price has changed by 3.30%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.93%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.9%
In Past 3 Month
Stock Price
Go Up
up Image
+3.30%
In Past 3 Month
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
10 Hold
1 Sell
Hold
Current: 25.700
sliders
Low
24.00
Averages
29.08
High
34.00
Current: 25.700
sliders
Low
24.00
Averages
29.08
High
34.00
Guggenheim
Buy
maintain
$33 -> $35
2025-11-24
Reason
Guggenheim
Price Target
$33 -> $35
2025-11-24
maintain
Buy
Reason
Guggenheim raised the firm's price target on Pfizer to $35 from $33 and keeps a Buy rating on the shares. Pfizer's acquisition of Metsera is "a wise strategic move" to gain traction in the rapidly growing obesity market following recent setbacks with the company's internal oral GLP-1 programs, the analyst tells investors.
Scotiabank
Outperform
initiated
$30
2025-11-12
Reason
Scotiabank
Price Target
$30
2025-11-12
initiated
Outperform
Reason
Scotiabank initiated coverage of Pfizer with an Outperform rating and $30 price target.
BofA
Tim Anderson
Neutral
maintain
$28
2025-10-01
Reason
BofA
Tim Anderson
Price Target
$28
2025-10-01
maintain
Neutral
Reason
The timing of the "deal" announced between the U.S. and Pfizer on drug pricing "may have come as a surprise," but the substance of it didn't, in the opinion of BofA analyst Tim Anderson, whose view over the last weeks-to-months has been that the drug industry might well escape any real pain when negotiating on issues like "most favored nation" drug pricing. Press releases from the White House and from Pfizer "largely lack specifics, but both read as benign," adds the analyst, who calls the agreement "a loose collection of measures that likely doesn't cost Pfizer much, yet still provides the Administration with a political win." The firm keeps a Neutral rating and $28 price target on Pfizer shares.
Wells Fargo
Cerena Chen
Overweight -> Equal Weight
downgrade
$65 -> $54
2025-09-29
Reason
Wells Fargo
Cerena Chen
Price Target
$65 -> $54
2025-09-29
downgrade
Overweight -> Equal Weight
Reason
Wells Fargo analyst Cerena Chen downgraded Metsera (MTSR) to Equal Weight from Overweight with a price target of $54, down from $65, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets. The firm adds that here's little likelihood of other bidders coming in at this time as other players have likely already looked at the company.
BofA
Buy -> Neutral
downgrade
$16 -> $10
2025-09-23
Reason
BofA
Price Target
$16 -> $10
2025-09-23
downgrade
Buy -> Neutral
Reason
BofA downgraded Arvinas (ARVN) to Neutral from Buy with a price target of $10, down from $16. The firm cites the company and Pfizer (PFE) announcing that they plan to find a partner to develop metastatic breast cancer drug vepdeg, the analyst tells investors in a research note. BofA notes that the pan calling for selecting a 3rd party to out-license the dug "introduces significant uncertainty" around the timing of vepdeg commercialization.
Citi
Geoff Meacham
Neutral
maintain
$25 -> $26
2025-08-06
Reason
Citi
Geoff Meacham
Price Target
$25 -> $26
2025-08-06
maintain
Neutral
Reason
Citi analyst Geoff Meacham raised the firm's price target on Pfizer to $26 from $25 and keeps a Neutral rating on the shares. The company reported strong Q2 results but policy headwinds warrant a continued cautious stance, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Pfizer Inc (PFE.N) is 8.59, compared to its 5-year average forward P/E of 12.28. For a more detailed relative valuation and DCF analysis to assess Pfizer Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
12.28
Current PE
8.59
Overvalued PE
18.60
Undervalued PE
5.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.96
Undervalued EV/EBITDA
6.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.88
Current PS
0.00
Overvalued PS
3.42
Undervalued PS
2.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PFE News & Events

Events Timeline

(ET)
2025-12-04
10:20:00
FDA Plans to Reduce Drug Approval Trials, Shares of Icon and Others Drop
select
2025-12-04
09:50:00
FDA Plans to Simplify Medical Product Approvals to One Clinical Study
select
link
2025-12-02 (ET)
2025-12-02
11:30:00
FDA Drug Regulator Richard Pazdur to Retire at Month-End
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-04Globenewswire
Sickle Cell Disease Market Expected to Grow 22.1% by 2034 Driven by New Therapies
  • Market Growth Potential: The sickle cell disease market is projected to grow at a CAGR of 22.1% from 2025 to 2034, primarily driven by advancements in new therapies and disease mechanisms, thereby presenting significant opportunities for pharmaceutical companies.
  • Market Size: In 2024, the sickle cell disease market size reached $650 million, with the United States accounting for approximately 87% of the total market share, indicating the dominant position of the U.S. while also reflecting growth potential in other markets.
  • Emerging Therapies Launch: New therapies such as Pfizer's inclacumab and Novo Nordisk's etavopivat are under development and are expected to significantly alter the market landscape, providing patients with more effective treatment options and enhancing overall treatment outcomes.
  • Rising Patient Demand: The number of sickle cell disease cases is anticipated to rise to 178,500 by 2034, predominantly among individuals aged 18 to 44, which will drive demand for new therapies and further stimulate market growth.
[object Object]
Preview
8.0
12-03NASDAQ.COM
PFE Options for June 2027 Now Available for Trading

  • Put Contract Analysis: The $18.00 put contract for Pfizer (PFE) has a bid of 61 cents, allowing investors to potentially buy shares at a cost basis of $17.39, which is a 30% discount from the current price of $25.69. There is a 79% chance the contract may expire worthless, offering a 3.39% return on cash commitment.

  • Call Contract Strategy: The $27.00 call contract has a bid of $2.00, allowing investors to sell shares at that price if they buy at $25.69. This could yield a total return of 12.88% if exercised, but there is a 49% chance it may expire worthless, providing a 7.79% additional return if it does.

  • Volatility Insights: The implied volatility for the put contract is 55%, while the call contract's implied volatility is 39%. The actual trailing twelve-month volatility for PFE is calculated at 27%.

  • YieldBoost Concept: The article discusses the concept of YieldBoost, which refers to the additional returns investors can earn from options contracts, highlighting the potential benefits of both put and call strategies for PFE stock.

[object Object]
Preview
8.0
12-03MarketWatch
17 Bargain Dividend Stocks Recommended by a Highly Successful Value Manager

  • Market Trends and Diversification: The financial media often focuses on market trends like artificial intelligence and asset price increases, but emphasizes the importance of maintaining a diversified investment portfolio.

  • Expert Insights: John Buckingham, a value-oriented portfolio manager, provided a list of 30 dividend stocks rated as "buy" by his team, highlighting the significance of selecting undervalued stocks.

  • Stock Selection Criteria: The list was refined to 17 stocks that trade at low multiples compared to expected earnings per share, offering potential investment opportunities.

  • Comparison with S&P 500: The selected stocks are evaluated against the S&P 500, indicating their relative value and potential for growth in a diversified portfolio.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Pfizer Inc (PFE) stock price today?

The current price of PFE is 25.7 USD — it has increased 0.51 % in the last trading day.

arrow icon

What is Pfizer Inc (PFE)'s business?

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

arrow icon

What is the price predicton of PFE Stock?

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Pfizer Inc (PFE)'s revenue for the last quarter?

Pfizer Inc revenue for the last quarter amounts to 16.65B USD, decreased -5.92 % YoY.

arrow icon

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

Pfizer Inc. EPS for the last quarter amounts to 0.62 USD, decreased -20.51 % YoY.

arrow icon

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -0.93% over the past three months. During the same period, the stock price has changed by 3.30%.
arrow icon

How many employees does Pfizer Inc (PFE). have?

Pfizer Inc (PFE) has 81000 emplpoyees as of December 05 2025.

arrow icon

What is Pfizer Inc (PFE) market cap?

Today PFE has the market capitalization of 146.12B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free